Predictive Oncology Inc.

MUN:S1K Stock Report

Market Cap: €4.4m

Predictive Oncology Management

Management criteria checks 4/4

Predictive Oncology's CEO is Raymond Vennare, appointed in Nov 2022, has a tenure of 2.08 years. total yearly compensation is $525.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €4.72K. The average tenure of the management team and the board of directors is 2.1 years and 3.8 years respectively.

Key information

Raymond Vennare

Chief executive officer

US$525.0k

Total compensation

CEO salary percentage100.0%
CEO tenure2.1yrs
CEO ownership0.1%
Management average tenure2.1yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Raymond Vennare's remuneration changed compared to Predictive Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$15m

Dec 31 2023US$525kUS$525k

-US$14m

Sep 30 2023n/an/a

-US$17m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$639kUS$88k

-US$26m

Sep 30 2022n/an/a

-US$26m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$33kn/a

-US$20m

Compensation vs Market: Raymond's total compensation ($USD525.00K) is about average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: Raymond's compensation has been consistent with company performance over the past year.

CEO

Raymond Vennare (72 yo)

2.1yrs

Tenure

US$525,000

Compensation

Mr. Raymond F. Vennare is Chief Executive Officer and Chairman at Predictive Oncology Inc. from November 01, 2022. He Co-Founded ThermalTherapeutic Systems, Inc. in 2006 and served as its Executive Vice Pr...

Leadership Team

NamePositionTenureCompensationOwnership
Raymond Vennare
CEO & Chairman2.1yrsUS$525.00k0.11%
€ 4.7k
Joshua Blacher
Interim Chief Financial Officer1.3yrsno datano data
Theresa Ferguson
Senior Director of Marketing2.7yrsno datano data
Lawrence DeLucas
Senior Vice President of Biologicsno datano datano data
Arlette Uihlein
Senior VP of Translational Medicine & Drug Discovery and Medical Directorno datano datano data

2.1yrs

Average Tenure

Experienced Management: S1K's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Raymond Vennare
CEO & Chairman3.3yrsUS$525.00k0.11%
€ 4.7k
Bernard Harris
Member of Business Advisory Board1.5yrsno datano data
Charles Nuzum
Lead Independent Director4.4yrsUS$98.90kno data
Andrew Einhorn
Member of Business Advisory Board1.5yrsno datano data
Veena Rao-Mirmira
Independent Director1.6yrsUS$73.34k0.14%
€ 6.0k
Marc Malandro
Member of Scientific Advisory Board6.3yrsno datano data
Daniel Handley
Independent Director4.8yrsUS$54.45k0.23%
€ 10.2k
Robert Murphy
Member of Scientific Advisory Board6.3yrsno datano data
Matthew Hawryluk
Independent Director2.1yrsUS$65.56k0.14%
€ 6.3k
Nancy Chung-Welch
Independent Director4.4yrsUS$76.67k0.26%
€ 11.5k
Gregory St. Clair
Independent Director4.4yrsUS$65.56k0.30%
€ 13.2k
Christoph Reinhard
Member of Scientific Advisory Board1.7yrsno datano data

3.8yrs

Average Tenure

64yo

Average Age

Experienced Board: S1K's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:56
End of Day Share Price 2024/10/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Predictive Oncology Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Vernon BernardinoH.C. Wainwright & Co.